FDA panel rules against NeurogesX patch for HIV
WASHINGTON (Reuters) - A Food and Drug Administration panel of outside experts on Thursday ruled against using a pain-relief product derived from chili peppers to treat the pain that afflicts many HIV patients suffer in their extremities.
In a 12-0 vote, the FDA advisory committee found that clinical data did not show substantial evidence that NeurogesX Inc's Qutenza capsaicin patch was effective at treating neuropathic pain among people infected with the virus that causes AIDS.
The panel also voted 11-0, with one abstention, that Qutenza's risk-benefit profile was not acceptable for use in HIV patients.
(Reporting By David Morgan; Editing by Gerald E. McCormick)
- Divided, Scots prepare to vote on fate of the United Kingdom |
- Scots vote in independence referendum to seal the United Kingdom's fate |
- Dollar hits six-year peak versus yen, ECB aims cash hose
- Apple to unveil new iPads, operating system on Oct. 21: report
- Australian PM says police raids follow IS linked beheading plot
Major U.S. poultry firms are administering antibiotics to their flocks far more pervasively than regulators realize, posing a potential risk to human health. Full Article